<!DOCTYPE html>
<html lang="en">
<head>
    <!-- [META TAGS] -->
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    <meta http-equiv="X-UA-Compatible" content="ie=edge">

    <!-- [CSS FILES] -->
    <link rel="stylesheet" href="css/normalize.css">
    <link rel="stylesheet" href="css/font-awesome.min.css">
    <link rel="stylesheet" href="css/bootstrap.min.css">
    <link rel="stylesheet" href="css/style.css">

    <title>Mind Mapping</title>
</head>
<body>

    <!-- START: main-container -->
    <div id="main-container">
        
        <div class="sign-out col-sm-12 col-xs-4">
            <i class="fa fa-sign-out">Logout</i>
        </div>

        <div id="branding-logos" class="branding-logos">
            <img class="mind-mapping-logo" src="./media/imgs/S0_082_resized.png" alt="mind-mapping-logo">
            <img class="merck-logo-01" src="./media/imgs/S0_012.png" alt="merck-logo-01">
            <img class="merck-logo-02" src="./media/imgs/S0_022.png" alt="merck-logo-02">
            <img class="concor-logo" src="./media/imgs/S0_042.png" alt="concor-logo">
        </div>
        
        <!-- START: icons-container -->
        <div id="icons-container">
            
            <div class="row"></div>
            
            <div class="row" style="text-align: center">
                <div class="col-xs-1"></div>
                <div class="col-xs-2" style="text-align: center">
                    <img class="molecules-icon img-responsive" src="./media/imgs/S332.png" alt="molecules">
                </div>
                <div class="col-xs-2" style="text-align: center">
                    <img class="renal-icon img-responsive" src="./media/imgs/S0_062.png" alt="renal">
                </div>
                <div class="col-xs-2" style="text-align: center">
                    <img class="male-icon img-responsive" src="./media/imgs/S0_21.png" alt="male">
                </div>
                <div class="col-xs-2" style="text-align: center">
                    <img class="jnc-icon img-responsive" src="./media/imgs/S0_16.png" alt="jnc">
                </div>
                <div class="col-xs-2" style="text-align: center">
                    <img class="liver-icon img-responsive" src="./media/imgs/S0_20.png" alt="liver">
                </div>
            </div>
            
            
            <div class="row">
                <div class="col-xs-1"></div>
                <div class="col-xs-2" style="text-align: center">
                    <img class="ascot-claims-icon img-responsive" src="./media/imgs/S0_14_alt.png" alt="ascot-claims">
                </div>
                <div class="col-xs-6"></div>
                <div class="col-xs-2" style="text-align: center">
                    <img class="brady-icon img-responsive" src="./media/imgs/S0_18_alt.png" alt="brady">
                </div>
            </div>
            
                    
            <div class="row">
                <div class="col-xs-1"></div>
                <div class="col-xs-2" style="text-align: center">
                    <img class="diabetic-icon img-responsive" src="./media/imgs/S0_25.png" alt="diabetic">
                </div>
                <div class="col-xs-2" style="text-align: center">
                    <img class="misc-icon img-responsive" src="./media/imgs/S_143.png" alt="misc">
                </div>
                <div class="col-xs-2" style="text-align: center">
                    <img class="lipid-icon img-responsive" src="./media/imgs/S0_172_alt.png" alt="lipid">
                </div>
                <div class="col-xs-2" style="text-align: center">
                    <img class="eye-icon img-responsive" src="./media/imgs/S0_22.png" alt="eye">
                </div>
                <div class="col-xs-2" style="text-align: center">
                    <img class="nightmare-icon img-responsive" src="./media/imgs/S0_15.png" alt="nightmare">
                </div>
                
                <div class="row"></div>
                
            </div>
                    
        </div>
        <!-- END: icons-container -->
        
    </div>
    <!-- END: main-container -->

    <!-- START: content-container -->
    <div id="content-container">

        <!-- START: molecules-container section 01 -->
        <div class="molecules-container col-xs-12">
            <i class="fa fa-home" aria-hidden="true"></i>

            <img class="molecules-icon-alt" src="./media/imgs/S332.png" alt="molecules">

            <ul class="main-ul">
                <li><a class="link01">Atenolol vs Bisoprolol as a Cardioprotective.</a></li>
                <li><a class="link02">Nebivolol handling.</a></li>
                <li><a class="link03">Concor vs Nebivolol in the terms of cardio-selectivity.</a></li>
                <li><a class="link04">Metoprolol Handling.</a></li>
            </ul>

            <!-- START: sub-container  section 01 -->
            <div class="sub-container col-xs-12">

                <!-- START: first-container section 01  -->
                <div class="first-container">
                    <i class="fa fa-times" aria-hidden="true"></i>                            

                    <ul class="secondary-ul">
                        <li>Both Beta Blockers are equipotent on Heart Rate Reduction thus Cardioprotective.<sup>(1)</sup></li>
                        <li>Bisoprolol but not Atenolol covers the 24 hours by a once daily dose especially in the morning early hours (peak of sympathetic surge).<sup>(2)</sup></li>
                        <li>Bisoprolol but not Atenolol is proven to reduce All-Cause Mortality &amp; Sudden Cardiac Death in Heart Failure (CIBIS trial).<sup>(3,4)</sup></li>
                        <li>Bisoprolol but not Atenolol has a neutral impact on lipid profile.<sup>(5)</sup></li>
                    </ul>

                    <ul class="ref-btn-group">
                        <li><a id="btn-ref-1" fk_mind_id="1" pdf_name="1. Ateno - Biso effects on Heart Rate_5481">Ref 1 |</a></li>
                        <li><a id="btn-ref-2" fk_mind_id="1" pdf_name="2. Ateno - Biso effect on ABPM_5894">Ref 2 |</a></li>
                        <li><a id="btn-ref-3" fk_mind_id="1" pdf_name="3. ESC Guidelines 2016_67490">Ref 3 |</a></li>
                        <li><a id="btn-ref-4" fk_mind_id="1" pdf_name="4. CIBIS II Study_4210">Ref 4 |</a></li>
                        <li><a id="btn-ref-5" fk_mind_id="1" pdf_name="5. Impact on Lipids_4140">Ref 5</a></li>
                    </ul>

                </div>
                <!-- END: first-container  section 01 -->


                <!-- START: second-container  section 01 -->
                <div class="second-container">
                    <i class="fa fa-times" aria-hidden="true"></i>                            

                    <ul class="secondary-ul">
                        <li>Nebivolol is inferior in the terms of Heart Rate reduction (due to ISA: Prof. Cruickshank article on Beta Blockers).<sup>(1,2,3)</sup></li>
                        <li>No definite bioavailability (highly depENDent on fast vs slow metabolizers).<sup>(4)</sup></li>
                        <li>No definite half-life (8 to 27 hours).<sup>(4)</sup></li>
                        <li>No Balanced Clearance (Contraindicated with liver disease).<sup>(4)</sup></li>
                        <li>Needed dose adjustment with renal patients.<sup>(4)</sup></li>
                        <li>L-Arginine pathway leading to harmful effects on the myocardium increasing mortality rates especially post infarction.<sup>(1)</sup></li>
                        <li>Nebivolol is not indicated in Coronary Artery Disease.<sup>(4)</sup></li>
                    </ul>

                    <ul class="ref-btn-group">
                        <li><a id="btn-ref-6" fk_mind_id="1" pdf_name="1. Cruickshank Int J Cardiol 2007_14292">Ref 1 |</a></li>
                        <li><a id="btn-ref-7" fk_mind_id="1" pdf_name="2. Nebivolol 3rd generation_10104">Ref 2 |</a></li>
                        <li><a id="btn-ref-8" fk_mind_id="1" pdf_name="3. Nebivolol vs Atenolol_5558">Ref 3 |</a></li>
                        <li><a id="btn-ref-9" fk_mind_id="1" pdf_name="4. Moen MD, Wagstaff AJ. Nebivolol_15120">Ref 4</a></li>
                    </ul>

                </div>
                <!-- END: second-container -->


                <!-- START: third-container -->
                <div class="third-container">
                    <i class="fa fa-times" aria-hidden="true"></i>                            

                    <ul class="secondary-ul">
                        <li>Based on studies done on hamster, Nebivolol is more selective than Concor, however based on studies done on human myocardial cells, Concor is more selective.<sup>(1,2)</sup></li>
                        <li>All benefits from cardio-selectivity are highly achieved with Concor. (e.g. safety in COPD patients).<sup>(3)</sup></li>
                        <li>Nebivolol is contraindicated in asthma – check insert (same for Concor).<sup>(4)</sup></li>
                    </ul>

                    <ul class="ref-btn-group">
                        <li><a id="btn-ref-10" fk_mind_id="1" pdf_name="1. Cruickshank Int J Cardiol 2007_14292">Ref 1 |</a></li>
                        <li><a id="btn-ref-11" fk_mind_id="1" pdf_name="2. Concor Selectivity on Human Myocardium Cells_7940">Ref 2 |</a></li>
                        <li><a id="btn-ref-12" fk_mind_id="1" pdf_name="3. approved insert_Concor Eng_10104">Ref 3 |</a></li>
                        <li><a id="btn-ref-13" fk_mind_id="1" pdf_name="4. Moen MD, Wagstaff AJ. Nebivolo_15120">Ref 4</a></li>
                    </ul>

                </div>
                <!-- END: third-container -->


                <!-- START: fourth-container -->
                <div class="fourth-container">
                    <i class="fa fa-times" aria-hidden="true"></i>                            

                    <ul class="secondary-ul">
                        <li>Concor selectivity on Beta 1 Receptors is double that of Metoprolol.<sup>(1)</sup></li>
                        <li>Concor unique Balanced Clearance.<sup>(2,3)</sup></li>
                        <li>Concor superiority in the reduction of Heart Rate especially in the early morning hours.<sup>(4)</sup></li>
                        <li>Hepatic exclusive metabolism.<sup>(2)</sup></li>
                    </ul>

                    <ul class="ref-btn-group">
                        <li><a id="btn-ref-14" fk_mind_id="1" pdf_name="1. Bisoprolol Selectivity_3368">Ref 1 |</a></li>
                        <li><a id="btn-ref-15" fk_mind_id="1" pdf_name="2. Balanced Clearance_5859">Ref 2 |</a></li>
                        <li><a id="btn-ref-16" fk_mind_id="1" pdf_name="3. Balanced Clearance - 2_3865">Ref 3 |</a></li>
                        <li><a id="btn-ref-17" fk_mind_id="1" pdf_name="4. China CREATIVE study full article_6328">Ref 4</a></li>
                    </ul>

                </div>
                <!-- END: fourth-container -->

            </div>
            <!-- END: sub-container -->

        </div>
        <!-- END: molecules-container -->

        <!-- ******************************************************************************** -->

        <!-- START: renal-container -->
        <div class="renal-container">
            <i class="fa fa-home" aria-hidden="true"></i>

            <img class="renal-icon-alt" src="./media/imgs/S0_062.png" alt="renal">

            <ul class="main-ul">
                <li><a class="link01"href="#">What is the effect of Concor Plus on Renal Patients?</a></li>
                <li><a class="link02"href="#">Concor decrease renal flow</a></li>
                <li><a class="link03"href="#">Concor in Renal Failure</a></li>
            </ul>


            <!-- START: sub-container -->
            <div class="sub-container">

                <!-- START: first-container -->
                <div class="first-container">
                    <i class="fa fa-times" aria-hidden="true"></i>                            

                    <ul class="secondary-ul">
                        <li>With normal kidneys the elimination half-life of Hydrochlorothiazide is 2.5 hours.<sup>(1)</sup></li>
                        <li>Concor Plus is contraindicated with severe renal disease (creatinine clearance &#60; 30 mL/min).<sup>(2)</sup></li>
                    </ul>

                    <ul class="ref-btn-group">
                        <li><a id="btn-ref-18" fk_mind_id="2" pdf_name="1. approved insert_Concor Eng_10104">Ref 1 |</a></li>
                        <li><a id="btn-ref-19" fk_mind_id="2" pdf_name="2. Approved insert of Concor 5 & 10 plus_8420">Ref 2</a></li>
                    </ul>

                </div>
                <!-- END: first-container -->


                <!-- START: second-container -->
                <div class="second-container">
                    <i class="fa fa-times" aria-hidden="true"></i>                            

                    <ul class="secondary-ul">
                        <li>The study performed by Parinnello on Concor vs Losartan proved that Concor does not reduce renal blood flow.<sup>(1)</sup></li>
                        <li>Concor can be used in renal patients.<sup>(2)</sup></li>
                    </ul>

                    <ul class="ref-btn-group">
                        <li><a id="btn-ref-20" fk_mind_id="2" pdf_name="1. Parrinello2009_8151">Ref 1 |</a></li>
                        <li><a id="btn-ref-21" fk_mind_id="2" pdf_name="2. approved insert_Concor Eng_10104">Ref 2</a></li>
                    </ul>

                </div>
                <!-- END: second-container -->


                <!-- START: third-container -->
                <div class="third-container">
                    <i class="fa fa-times" aria-hidden="true"></i>                            

                    <ul class="secondary-ul">
                        <li>The dose of Concor does not need any adjustment for mild to moderate renal disease. In patients with severe renal disease (creatinine clearance &lt; 20 ml/min) a daily dose of 10 mg.<sup>(1)</sup></li>
                        <li>Balanced Clearance is an exclusive advantage in Concor, thus suitable for both renal &amp; hepatic impairment diseases.<sup>(1,2,3)</sup></li>
                    </ul>

                    <ul class="ref-btn-group">
                        <li><a id="btn-ref-22" fk_mind_id="2" pdf_name="1. approved insert_Concor Eng_10104">Ref 1 |</a></li>
                        <li><a id="btn-ref-23" fk_mind_id="2" pdf_name="2. Balanced Clearance_5859">Ref 2 |</a></li>
                        <li><a id="btn-ref-24" fk_mind_id="2" pdf_name="3. Balanced Clearance - 2_3865">Ref 3</a></li>
                    </ul>

                </div>
                <!-- END: third-container -->

            </div>
            <!-- END: sub-container -->

        </div>
        <!-- END: renal-container -->

        <!-- ******************************************************************************** -->

        <!-- START: male-container -->
        <div class="male-container">
            <i class="fa fa-home" aria-hidden="true"></i>

            <img class="male-icon-alt" src="./media/imgs/S0_21.png" alt="male">
            <ul class="main-ul">
                <li><a class="link01"href="#">Sexual impotance claims of Concor</a></li>
            </ul>

            <!-- START: sub-container -->
            <div class="sub-container">

                <!-- START: first-container -->
                <div class="first-container">
                    <i class="fa fa-times" aria-hidden="true"></i>                            

                    <ul class="secondary-ul">
                        <li>Impact on potency is generally rare with Concor.<sup>(1)</sup></li>
                        <li>Concor incidence of erectile dysfunction is less than placebo.<sup>(2)</sup></li>
                        <li>Concor has minimal impact on potency compared to other Beta Blockers, Atenolol (3%), Propranolol (5%) and Carvedilol (13.5%).<sup>(3,4)</sup></li>
                        <li>Generally potency disorders are highly impacted by the psychic element and Cardiovascular Disease Progressive Status.<sup>(5)</sup></li>
                    </ul>

                    <ul class="ref-btn-group">
                        <li><a id="btn-ref-25" fk_mind_id="3" pdf_name="1. approved insert_Concor Eng_10104">Ref 1 |</a></li>
                        <li><a id="btn-ref-26" fk_mind_id="3" pdf_name="2. Self Reporting - Concor vs Placebo_4210">Ref 2 |</a></li>
                        <li><a id="btn-ref-27" fk_mind_id="3" pdf_name="3. Study in Journal of Sex & Marital Therapy_6696">Ref 3 |</a></li>
                        <li><a id="btn-ref-28" fk_mind_id="3" pdf_name="4. Different incidence of impotence with different Beta Blockers_1827">Ref 4 |</a></li>
                        <li><a id="btn-ref-29" fk_mind_id="3" pdf_name="5. Beta Blockers Safety_4710">Ref 5</a></li>
                    </ul>

                </div>
                <!-- END: first-container -->

            </div>
            <!-- END: sub-container -->

        </div>
        <!-- END: male-container -->

        <!-- ******************************************************************************** -->

        <!-- START: liver-container -->
        <div class="liver-container">
            <i class="fa fa-home" aria-hidden="true"></i>

            <img class="liver-icon-alt" src="./media/imgs/S0_20.png" alt="liver">

            <ul class="main-ul">
                <li><a class="link01"href="#">Concor taking drugs for the treatment of Hepatitis C</a></li>
            </ul>

            <!-- START: sub-container -->
            <div class="sub-container">

                <!-- START: first-container -->
                <div class="first-container">
                    <i class="fa fa-times" aria-hidden="true"></i>                            

                    <ul class="secondary-ul">
                        <li>Concor can be co-administered with drugs for the treatment of Hepatitis C but with caution and monitoring of Heart Rate.</li>
                    </ul>

                    <ul class="ref-btn-group">
                        <li><a id="btn-ref-30" fk_mind_id="4" pdf_name="1. BBs and Portal Hypertension_10179">Ref 1</a></li>
                    </ul>

                </div>
                <!-- END: first-container -->

            </div>
            <!-- END: sub-container -->

        </div>
        <!-- END: liver-container -->

        <!-- ******************************************************************************** -->

        <!-- START: brady-container -->
        <div class="brady-container">
            <i class="fa fa-home" aria-hidden="true"></i>

            <img class="liver-icon-alt" src="./media/imgs/S0_18_alt.png" alt="liver">

            <ul class="main-ul">
                <li><a class="link01"href="#">Patient with a Heart Rate of 60, should continue or discontinue Concor?</a></li>
                <li><a class="link02"href="#">Concor dose regimen in Heart Failure</a></li>
                <li><a class="link03"href="#">Ivabradine reduces Heart Rate without impact on Ejection Fraction or Contractility</a></li>
            </ul>

            <!-- START: sub-container -->
            <div class="sub-container">

                <!-- START: first-container -->
                <div class="first-container">
                    <i class="fa fa-times" aria-hidden="true"></i>                            

                    <ul class="secondary-ul">
                        <li>No need to discontinue Concor at this level of Heart Rate, dose reduction is required for lower Heart Rate.<sup>(1)</sup></li>
                    </ul>

                    <ul class="ref-btn-group">
                        <li><a id="btn-ref-31" fk_mind_id="5" pdf_name="1. approved insert_Concor Eng_10104">Ref 1</a></li>
                    </ul>

                </div>
                <!-- END: first-container -->


                <!-- START: second-container -->
                <div class="second-container">
                    <i class="fa fa-times" aria-hidden="true"></i>                            

                    <ul class="secondary-ul">
                        <li>Concor dose escalation is the regimen in Heart Failure following the rule of start low, go slow.</li>
                        <li>Week 1: 1.25 mg once daily, Week 2: 2.5 mg once daily, Week 3: 3.75 mg once daily, Weeks 4-7: 5 mg, Weeks 8-11: 7.5 mg once daily and Week 12: 10 mg.<sup>(1)</sup></li>
                    </ul>

                    <ul class="ref-btn-group">
                        <li><a id="btn-ref-32" fk_mind_id="5" pdf_name="1. approved insert_Concor Eng">Ref 1</a></li>
                    </ul>

                </div>
                <!-- END: second-container -->


                <!-- START: third-container -->
                <div class="third-container">
                    <i class="fa fa-times" aria-hidden="true"></i>                            

                    <ul class="secondary-ul">
                        <li>International Guidelines of Coronary Artery Disease and Heart Failure consistently recommend Beta Blockers ahead of Ivabradine (Ivabradine are used in the case of contraindication to Beta Blockers or in the case of not achieving the target Heart Rate with the maximum tolerated dose of Beta Blockers).<sup>(1)</sup></li>
                    </ul>

                    <ul class="ref-btn-group">
                        <li><a id="btn-ref-33" fk_mind_id="5" pdf_name="1. ESC Guidelines 2016_67490">Ref 1</a></li>
                    </ul>

                </div>
                <!-- END: third-container -->

            </div>
            <!-- END: sub-container -->

        </div>
        <!-- END: brady-container -->

        <!-- ******************************************************************************** -->

        <!-- START: misc-container -->
        <div class="misc-container">
            <i class="fa fa-home" aria-hidden="true"></i>

            <img class="misc-icon-alt" src="./media/imgs/S_143.png" alt="misc">

            <ul class="main-ul">
                <li><a class="link01"href="#">Concor regarding fatigue and cough</a></li>
                <li><a class="link02"href="#">Is Concor safe with cold extremities?</a></li>
                <li><a class="link03"href="#">Concor not effective in hypertension</a></li>
                <li><a class="link04"href="#">ARBs in MI &amp; Heart Failure</a></li>
                <li><a class="link05"href="#">ACE-IS and anemia</a></li>
                <li><a class="link06"href="#">Concor with athletics</a></li>
                <li><a class="link07"href="#">Concor with pregnant female</a></li>
                <li><a class="link08"href="#">Concor use with Migraine</a></li>
                <li><a class="link09"href="#">In patients with PAD, it is logic to prefer a vasodilator Beta Block</a></li>
            </ul>

            <!-- START: sub-container -->
            <div class="sub-container">

                <!-- START: first-container -->
                <div class="first-container">
                    <i class="fa fa-times" aria-hidden="true"></i>                            

                    <ul class="secondary-ul">
                        <li>No reports for cough unlike ACE-Is, however fatigue is less common compared to less selective Beta Blockers (e.g. Atenolol).<sup>(1,2)</sup></li>
                    </ul>

                    <ul class="ref-btn-group">
                        <li><a id="btn-ref-34" fk_mind_id="6" pdf_name="1. approved insert_Concor Eng_10104">Ref 1 |</a></li>
                        <li><a id="btn-ref-35" fk_mind_id="6" pdf_name="2. Beta Blockers Safety_4716">Ref 2</a></li>
                    </ul>

                </div>
                <!-- END: first-container -->


                <!-- START: second-container -->
                <div class="second-container">
                    <i class="fa fa-times" aria-hidden="true"></i>                            

                    <ul class="secondary-ul">
                        <li>Contraindication occurs with the severe form of peripheral arterial disease (elderly patients).</li>
                        <li>Sensation of cold extremities may occur with Concor (use is based on risk/benefit ratio).<sup>(1)</sup></li>
                    </ul>

                    <ul class="ref-btn-group">
                        <li><a id="btn-ref-36" fk_mind_id="6" pdf_name="1. approved insert_Concor Eng_10104">Ref 1</a></li>
                    </ul>
                </div>
                <!-- END: second-container -->


                <!-- START: third-container -->
                <div class="third-container">
                    <i class="fa fa-times" aria-hidden="true"></i>                            

                    <ul class="secondary-ul">
                        <li>GENRES study showed superior reduction on systolic and diastolic blood pressure with Concor over ARBs, CCBs and Diuretics.<sup>(1)</sup></li>
                    </ul>

                    <ul class="ref-btn-group">
                        <li><a id="btn-ref-37" fk_mind_id="6" pdf_name="1. THE GENRES STUDY_6264">Ref 1</a></li>
                    </ul>
                </div>
                <!-- END: third-container -->


                <!-- START: fourth-container -->
                <div class="fourth-container">
                    <i class="fa fa-times" aria-hidden="true"></i>                            

                    <ul class="secondary-ul">
                        <li>Treasure of studies of ARBs showing either inferiority in MI reduction or increasing the incidence of MI.<sup>(1–8)</sup></li>
                    </ul>

                    <ul class="ref-btn-group">
                        <li><a id="btn-ref-38" fk_mind_id="6" pdf_name="1. RAASinhibitors meta-anaEditorial Ruschitzka-Taddei EHJ2012_2382">Ref 1 |</a></li>
                        <li><a id="btn-ref-39" fk_mind_id="6" pdf_name="2. 19% increased MI VALUE Study_8420">Ref 2 |</a></li>
                        <li><a id="btn-ref-40" fk_mind_id="6" pdf_name="3. ARBs MI Paradox_14877">Ref 3 |</a></li>
                        <li><a id="btn-ref-41" fk_mind_id="6" pdf_name="4. Olmesartan increase CV Deaths_7119">Ref 4 |</a></li>
                        <li><a id="btn-ref-42" fk_mind_id="6" pdf_name="5. RAASinhibitors meta-ana vanVark EHJ2012_7940">Ref 5 |</a></li>
                        <li><a id="btn-ref-43" fk_mind_id="6" pdf_name="6. Fuchs, 2013, 44_1928">Ref 6 |</a></li>
                        <li><a id="btn-ref-44" fk_mind_id="6" pdf_name="7. HIJ CREATE_2382">Ref 7 |</a></li>
                        <li><a id="btn-ref-45" fk_mind_id="6" pdf_name="8. Olmesartan_8316">Ref 8</a></li>
                    </ul>
                </div>
                <!-- END: fourth-container -->


                <!-- START: fifth-container -->
                <div class="fifth-container">
                    <i class="fa fa-times" aria-hidden="true"></i>                            

                    <ul class="secondary-ul">
                        <li>Documented in the Text Book of Essential Hypertension Page 503.<sup>(1)</sup></li>
                    </ul>

                    <ul class="ref-btn-group">
                        <li><a id="btn-ref-46" fk_mind_id="6" pdf_name="1. Hypertension Principles (P. 503)_674622">Ref 1</a></li>
                    </ul>
                </div>
                <!-- END: fifth-container -->


                <!-- START: sixth-container -->
                <div class="sixth-container">
                    <i class="fa fa-times" aria-hidden="true"></i>                            

                    <ul class="secondary-ul">
                        <li>Concor doesn’t reduce exercise capacity.<sup>(1)</sup></li>
                    </ul>

                    <ul class="ref-btn-group">
                        <li><a id="btn-ref-47" fk_mind_id="6" pdf_name="1. Bisoprolol and Exercise_6264">Ref 1</a></li>
                    </ul>
                </div>
                <!-- END: sixth-container -->

                <!-- START: seventh-container -->
                <div class="seventh-container">
                    <i class="fa fa-times" aria-hidden="true"></i>                            

                    <ul class="secondary-ul">
                        <li>​Concor can be considered in the case of absolute necessity, the neonate should be monitored for bradycardia and hypoglycemia.<sup>(1)</sup></li>
                        <li>NB: ACE-Is &amp; ARBs are absolutely contraindicated.</li>
                        <li>Concor Plus is not recommended in pregnant women due to the potential of causing foeto-placental ischemia.<sup>(2)</sup></li>
                    </ul>

                    <ul class="ref-btn-group">
                        <li><a id="btn-ref-48" fk_mind_id="6" pdf_name="1. approved insert_Concor Eng_10104">Ref 1 |</a></li>
                        <li><a id="btn-ref-49" fk_mind_id="6" pdf_name="2. Approved English insert of Concor 5 & 10 plus_8420">Ref 1</a></li>
                    </ul>
                </div>
                <!-- END: seventh-container -->


                <!-- START: eighth-container -->
                <div class="eighth-container">
                    <i class="fa fa-times" aria-hidden="true"></i>                            

                    <ul class="secondary-ul">
                        <li>Limited data are available in this regards, however Migraine is known to be one of the rare indications for Beta Blockers.</li>
                    </ul>

                    <ul class="ref-btn-group">
                        <li><a id="btn-ref-50" fk_mind_id="6" pdf_name="EFNS_guideline_2009_drug_treatment_of_migraine_10962">Ref 1</a></li>
                    </ul>
                </div>
                <!-- END: eighth-container -->


                <!-- START: ninth-container -->
                <div class="ninth-container">
                    <i class="fa fa-times" aria-hidden="true"></i>

                    <ul class="secondary-ul">
                        <li>Surprisingly the use of vasodilator Beta Blocker leads to worsening of walking distance due to the impact of what is called “steel phenomenon”.<sup>(1)</sup></li>
                    </ul>

                    <ul class="ref-btn-group">
                        <li><a id="btn-ref-51" fk_mind_id="6" pdf_name="1. Beta Blockers in CV Medicine">Ref 1</a></li>
                    </ul>
                </div>
                <!-- END: ninth-container -->

            </div>
            <!-- END: sub-container -->



        </div>
        <!-- END: misc-container -->

        <!-- ******************************************************************************** -->

        <!-- START: lipid-container -->
        <div class="lipid-container">
            <i class="fa fa-home" aria-hidden="true"></i>

            <img class="lipid-icon-alt" src="./media/imgs/S0_172_alt.png" alt="lipid">

            <ul class="main-ul">
                <li><a class="link01"href="#">Concor impact on lipid profile</a></li>
            </ul>

            <!-- START: sub-container -->
            <div class="sub-container">

                <!-- START: first-container -->
                <div class="first-container">
                    <i class="fa fa-times" aria-hidden="true"></i>                            

                    <ul class="secondary-ul">
                        <li>Concor has minimal impact on lipid profile due to its cardio-selectivity.<sup>(1,2)</sup></li>
                    </ul>

                    <ul class="ref-btn-group">
                        <li><a id="btn-ref-52" fk_mind_id="7" pdf_name="1. Impact on Lipids_4140">Ref 1 |</a></li>
                        <li><a id="btn-ref-53" fk_mind_id="7" pdf_name="2. Bisoprolol Selectivity_3368">Ref 2</a></li>
                    </ul>
                </div>

            </div>
            <!-- END: sub-container -->


        </div>
        <!-- END: lipid-container -->

        <!-- ******************************************************************************** -->

        <!-- START: eye-container -->
        <div class="eye-container">
            <i class="fa fa-home" aria-hidden="true"></i>

            <img class="eye-icon-alt" src="./media/imgs/S0_22.png" alt="eye">

            <ul class="main-ul">
                    <li><a class="link01"href="#">Concor &amp; eye disorders</a></li>
            </ul>

            <!-- START: sub-container -->
            <div class="sub-container">

                <!-- START: first-container -->
                <div class="first-container">
                    <i class="fa fa-times" aria-hidden="true"></i>                            

                    <ul class="secondary-ul">
                        <li>Both the incidence of Glaucoma &amp; Cataract are not reported to be caused by Concor / Concor Plus.<sup>(1,2)</sup></li>
                    </ul>

                    <ul class="ref-btn-group">
                        <li><a id="btn-ref-54" fk_mind_id="8" pdf_name="1. approved insert_Concor Eng_10104">Ref 1 |</a></li>
                        <li><a id="btn-ref-55" fk_mind_id="8" pdf_name="2. Approved English insert of Concor 5 & 10 plus_8420">Ref 2</a></li>
                    </ul>
                </div>
                <!-- END: first-container -->

            </div>
            <!-- END: sub-container -->


        </div>
        <!-- START: eye-container -->

        <!-- ******************************************************************************** -->

        <!-- START: nightmare-container -->
        <div class="nightmare-container">
            <i class="fa fa-home" aria-hidden="true"></i>

            <img class="nightmare-icon-alt" src="./media/imgs/S0_15.png" alt="nightmare">

            <ul class="main-ul">
                <li><a class="link01"href="#">Concor &amp; nightmares</a></li>
            </ul>

            <!-- START: sub-container -->
            <div class="sub-container">

                <!-- START: first-container -->
                <div class="first-container">
                    <i class="fa fa-times" aria-hidden="true"></i>                            

                    <ul class="secondary-ul">
                        <li>The incidence of nightmares and Concor is rare, however it is more common with highly lipophilic Beta Blockers (e.g. Propranolol &amp; Metoprolol).<sup>(1,2)</sup></li>
                    </ul>

                    <ul class="ref-btn-group">
                        <li><a id="btn-ref-56" fk_mind_id="9" pdf_name="1. approved insert_Concor Eng_10104">Ref 1 |</a></li>
                        <li><a id="btn-ref-57" fk_mind_id="9" pdf_name="2. Beta Blockers Safety_4716">Ref 2</a></li>
                    </ul>
                </div>
                <!-- END: first-container -->

            </div>
            <!-- END: sub-container -->

        </div>
        <!-- END: nightmare-container -->

        <!-- ******************************************************************************** -->

        <!-- START: jnc-container -->
        <div class="jnc-container">
            <i class="fa fa-home" aria-hidden="true"></i>

            <img class="jnc-icon-alt" src="./media/imgs/S0_16.png" alt="jnc">

            <ul class="main-ul">
                <li><a class="link01"href="#">JNC 8 claims</a></li>
            </ul>

            <!-- START: sub-container -->
            <div class="sub-container">

                <!-- START: first-container -->
                <div class="first-container">
                    <i class="fa fa-times" aria-hidden="true"></i>                            

                    <ul class="secondary-ul">
                        <li>JNC 8 mainly consists of Experts Opinion (Grade E) recommendations.<sup>(1)</sup></li>
                        <li>These Recommendations are not a substitute for Clinical Judgments, Decision about Care must carefully consider the Clinical Characteristics &amp; Circumstances of Individual Patients. (1,2)</li>
                        <li>Not based on Systemic Review &amp; Meta-Analyses neither Pre-Published nor done by the Panel.<sup>(1)</sup></li>
                        <li>Not a Comprehensive Guidelines, with limited Scope of Evidence Review without taking in consideration other Co-Morbidities, rather considered as evidence review.<sup>(1)</sup></li>
                        <li>This Report is not an NHLBI and does not reflect the views of NHLBI. (1)</li>
                        <li>Panel didn’t reach agreement.<sup>(3)</sup></li>
                        <li>European Guidelines still keep Beta Blockers as First line of treatment due to the meta-analysis proving the cardioprotective effect.<sup>(4,5)</sup></li>
                    </ul>

                    <ul class="ref-btn-group">
                        <li><a id="btn-ref-58" fk_mind_id="10" pdf_name="1. JNC 8 2014_11088">Ref 1 |</a></li>
                        <li><a id="btn-ref-59" fk_mind_id="10" pdf_name="2. JNC 8 Critical Assessment 3_1584">Ref 2 |</a></li>
                        <li><a id="btn-ref-60" fk_mind_id="10" pdf_name="3. Panel disagreement_4668">Ref 3 |</a></li>
                        <li><a id="btn-ref-61" fk_mind_id="10" pdf_name="4. ESH-ESC Guidelines_57168">Ref 4 |</a></li>
                        <li><a id="btn-ref-62" fk_mind_id="10" pdf_name="5. Meta-ana 147 trials BMJ2009_1586">Ref 5</a></li>
                    </ul>
                </div>
                <!-- END: first-container -->

            </div>
            <!-- END: sub-container -->

        </div>
        <!-- END: jnc-container -->

        <!-- ******************************************************************************** -->

        <!-- START: ascot-container -->
        <div class="ascot-container">
            <i class="fa fa-home" aria-hidden="true"></i>

            <img class="ascot-claims-icon-alt" src="./media/imgs/S0_14_alt.png" alt="ascot-claims">

            <ul class="main-ul">
                    <li><a class="link01"href="#">ASCOT trial handling (Anglo Scandinavian Cardiac Outcome Trial)</a></li>
            </ul>

            <!-- START: sub-container -->
            <div class="sub-container">

                <!-- START: first-container -->
                <div class="first-container">
                    <i class="fa fa-times" aria-hidden="true"></i>                            

                    <ul class="secondary-ul">
                        <li>European Hypertension Guidelines clarified the results displayed in ASCOT by the difference between the 2 comparative arms in systolic blood pressure by 2.7 mmHg.<sup>(1,2)</sup></li>
                        <li>ASCOT was performed on Atenolol which is unlike Bisoprolol is not the reference for the Beta Blockers (once daily) and do not properly cover the 24 hours, Atenolol half-life is 6-7.<sup>(3)</sup></li>
                        <li>Concor but not Atenolol reduces Central Aortic Pressure which has an impact on the incidence of strokes.<sup>(4)</sup></li>
                        <li>Results of ASCOT were not consistent with other studies like UKPDS.<sup>(5)</sup></li>
                        <li>Meta-Analysis published in the BMJ 2009 displayed the results on 464,000 showed Cardioprotective role of Beta Blockers and non-strokes in strokes reduction.<sup>(6)</sup></li>
                    </ul>

                    <ul class="ref-btn-group">
                        <li><a id="btn-ref-63" fk_mind_id="11" pdf_name="1. ESH ESC 2009 reappraisal_29716">Ref 1 |</a></li>
                        <li><a id="btn-ref-64" fk_mind_id="11" pdf_name="2. Prevention of risk factors_BB_2009 Prof_. G Mancia_4764">Ref 2 |</a></li>
                        <li><a id="btn-ref-65" fk_mind_id="11" pdf_name="3. Ateno - Biso effect on ABPM_5894">Ref 3 |</a></li>
                        <li><a id="btn-ref-66" fk_mind_id="11" pdf_name="4. bisoprolol-PLOSONE_6328">Ref 4 |</a></li>
                        <li><a id="btn-ref-67" fk_mind_id="11" pdf_name="5. UKPDS 39_7128">Ref 5</a></li>
                        <li><a id="btn-ref-68" fk_mind_id="11" pdf_name="6. Meta-ana 147 trials BMJ2009_15086">Ref 6</a></li>
                    </ul>
                </div>
                <!-- END: first-container -->

            </div>
            <!-- END: sub-container -->


        </div>
        <!-- END: ascot-container -->

        <!-- ******************************************************************************** -->

        <!-- START: diabetic-container -->
        <div class="diabetic-container">
            <i class="fa fa-home" aria-hidden="true"></i>

            <img class="diabetic-icon-alt" src="./media/imgs/S0_25.png" alt="diabetic">

            <ul class="main-ul">
                <li><a class="link01"href="#">Concor use with COPD, diabetic and pre-diabetic.</a></li>
                <li><a class="link02"href="#">Concor vs Carvedilol in the terms of new onset diabetes.</a></li>
                <li><a class="link03"href="#">Beta Blockers vs ACE-Is in Diabetic Hypertensive Patients.</a></li>
            </ul>

            <!-- START: sub-container -->
            <div class="sub-container">

                <!-- START: first-container -->
                <div class="first-container">
                    <i class="fa fa-times" aria-hidden="true"></i>                            

                    <ul class="secondary-ul">
                        <li>Due to its cardio-selectivity, Concor may be used in COPD patients if there is a compelling need.<sup>(1)</sup></li>
                        <li>No contraindication in diabetes, Concor due to its selectivity has neutral effect on glucose metabolism minimizing the incidence of new onset diabetes (unlike Atenolol), Beta receptors on the pancreas are mainly Beta-2.<sup>(1,2,3)</sup></li>
                    </ul>

                    <ul class="ref-btn-group">
                        <li><a id="btn-ref-69" fk_mind_id="12" pdf_name="1. approved insert_Concor Eng_10104">Ref 1 |</a></li>
                        <li><a id="btn-ref-70" fk_mind_id="12" pdf_name="2. Selective BBs & Serious Hypoglycemia_2936">Ref 2 |</a></li>
                        <li><a id="btn-ref-71" fk_mind_id="12" pdf_name="3. Prevention of risk factors_BB_2009 Prof. G Mancia_4764">Ref 3</a></li>
                    </ul>
                </div>
                <!-- END: first-container -->


                <!-- START: second-container -->
                <div class="second-container">
                    <i class="fa fa-times" aria-hidden="true"></i>                            

                    <ul class="secondary-ul">
                        <li>Neither Concor nor Carvedilol cause new onset diabetes.<sup>(1)</sup></li>
                        <li>Delayed Renal Excretion in elderly.<sup>(2)</sup></li>
                        <li>Carvedilol may worsen the case with COPD.<sup>(3)</sup></li>
                        <li>Carvedilol is inferior to Concor in terms of Heart Rate reduction.<sup>(4)</sup></li>
                        <li>Carvedilol causes new onset anemia proved in COMET trial &amp; CIBIS ELD.<sup>(5,6)</sup></li>
                        <li>Carvedilol is used twice daily.<sup>(2)</sup></li>
                    </ul>

                    <ul class="ref-btn-group">
                        <li><a id="btn-ref-72" fk_mind_id="12" pdf_name="1. Prevention of risk factors_BB_2009 Prof. G Mancia_4764">Ref 1 |</a></li>
                        <li><a id="btn-ref-73" fk_mind_id="12" pdf_name="2. Carvedilol in Hypertension_6336">Ref 2 |</a></li>
                        <li><a id="btn-ref-74" fk_mind_id="12" pdf_name="3. Biso vs Carve CHF COPD_4752">Ref 3 |</a></li>
                        <li><a id="btn-ref-75" fk_mind_id="12" pdf_name="4. Biso vs Carvi on Heart Rate_4210">Ref 4 |</a></li>
                        <li><a id="btn-ref-76" fk_mind_id="12" pdf_name="5. CIBIS-ELD Results Duengen EJHF2011 print_8734">Ref 5 |</a></li>
                        <li><a id="btn-ref-77" fk_mind_id="12" pdf_name="6. CHF anemia COMET EHJ 2006_5558">Ref 6</a></li>
                    </ul>
                </div>
                <!-- END: second-container -->


                <!-- START: third-container -->
                <div class="third-container">
                    <i class="fa fa-times" aria-hidden="true"></i>                            

                    <ul class="secondary-ul">
                        <li>Diabetic hypertensive patients usually need combination therapy to achieve the blood pressure target control.<sup>(1,2)</sup></li>
                        <li>Diabetic hypertensive patients are sympathetic driven as well as being coronary risk equivalent (silent ischemia), thus of high need for Beta Blockers.<sup>(3,4,5)</sup></li>
                        <li>Both ACE-Is and Beta Blockers are proven to protect kidneys and heart.<sup>(6,7)</sup></li>
                        <li>The edge of Beta Blockers over ACE-Is is the unique action to reduce Heart Rate.</li>
                        <li>Concor as a Beta1 selective BB, do not mask the symptoms of hypoglycemia.<sup>(8)</sup></li>
                    </ul>

                    <ul class="ref-btn-group">
                        <li><a id="btn-ref-78" fk_mind_id="12" pdf_name="1. ESH-ESC 2013_57168">Ref 1 |</a></li>
                        <li><a id="btn-ref-79" fk_mind_id="12" pdf_name="2. Multiple Therapy in Diabetics_8613">Ref 2 |</a></li>
                        <li><a id="btn-ref-80" fk_mind_id="12" pdf_name="3. Diabetes and Sympathetic_4698">Ref 3 |</a></li>
                        <li><a id="btn-ref-81" fk_mind_id="12" pdf_name="4. Diabetes Coronary Risk_2349">Ref 4 |</a></li>
                        <li><a id="btn-ref-82" fk_mind_id="12" pdf_name="5. Silent Ischemia with Diabetics_5052">Ref 5 |</a></li>
                        <li><a id="btn-ref-83" fk_mind_id="12" pdf_name="6. Parrinello2009_8151">Ref 6 |</a></li>
                        <li><a id="btn-ref-84" fk_mind_id="12" pdf_name="7. UKPDS 39_7128">Ref 7 |</a></li>
                        <li><a id="btn-ref-85" fk_mind_id="12" pdf_name="8. Selective BBs & Serious Hypoglycemia_2936">Ref 8</a></li>
                    </ul>
                </div>
                <!-- END: third-container -->

            </div>
            <!-- END: sub-container -->

        </div>
        <!-- END: diabetic-container -->

    </div>
    <!-- END: content-container -->
        
    


    <!-- [SCRIPTS GOES DOWN HERE] -->

    <!-- jQuery -->
    <script src="js/jquery-1.12.4.min.js"></script>

    <!-- TweenMax -->
    <script src="js/TweenMax.min.js"></script>
    
    <script src="js/jockey.js"></script>

    <!-- Custom Script -->
    <script src="js/script.js"></script>

</body>
</html>